Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma

Show full item record



Permalink

http://hdl.handle.net/10138/318890

Citation

Kuitunen , H , Kaprio , E , Karihtala , P , Makkonen , V , Kauppila , S , Haapasaari , K-M , Kuusisto , M , Jantunen , E , Turpeenniemi-Hujanen , T & Kuittinen , O 2020 , ' Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma ' , Annals of Hematology , vol. 99 , no. 8 , pp. 1823-1831 . https://doi.org/10.1007/s00277-020-04140-0

Title: Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
Author: Kuitunen, Hanne; Kaprio, Elina; Karihtala, Peeter; Makkonen, Ville; Kauppila, Saila; Haapasaari, Kirsi-Maria; Kuusisto, Milla; Jantunen, Esa; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi
Contributor: University of Helsinki, Department of Oncology
Date: 2020-08
Language: eng
Number of pages: 9
Belongs to series: Annals of Hematology
ISSN: 0939-5555
URI: http://hdl.handle.net/10138/318890
Abstract: Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is still a fatal complication of DLBCL. For this reason, CNS prophylaxis is recommended for patients at high risk of CNS disease. However, no consensus exists on definition of high-risk patient and optimal CNS prophylaxis. Systemic high-dose methotrexate in combination with R-CHOP has been suggested as a potential prophylactic method, since methotrexate penetrates the blood-brain barrier and achieves high concentration in the CNS. In this retrospective analysis, we report treatment outcome of 95 high-risk DLBCL/FL grade 3B patients treated with R-CHOP or its derivatives with (N = 57) or without (N = 38) CNS prophylaxis. At a median follow-up time (51 months), CNS relapses were detected in twelve patients (12.6%). Ten out of twelve (83%) of CNS events were confined to CNS system only. Median overall survival after CNS relapse was 9 months. Five-year isolated CNS relapse rates were 5% in the prophylaxis group and 26% in the group without prophylaxis. These findings suggest that high-dose methotrexate-containing prophylaxis decreases the risk of CNS failure.
Subject: Diffuse large B cell lymphoma
Central nervous system prophylaxis
High-dose methotrexate
Central nervous system recurrence
NON-HODGKINS-LYMPHOMA
MABTHERA INTERNATIONAL TRIAL
CHEMOTHERAPY PLUS RITUXIMAB
CELL LYMPHOMA
ELDERLY-PATIENTS
INTRATHECAL CHEMOTHERAPY
AGGRESSIVE LYMPHOMA
INTERMEDIATE-GRADE
RESPONSE CRITERIA
INVOLVEMENT
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Kuitunen2020_Ar ... CentralNervousSystemCN.pdf 535.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record